What 'Ozempic face' means for Canadian GLP-1 users: why beauty companies are racing to fix it

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

What is 'Ozempic face'?

As semaglutide (sold in Canada as Ozempic for type 2 diabetes, and Wegovy for chronic weight management) reshapes the bodies of hundreds of thousands of Canadians, a visible and largely unaddressed side effect has drawn attention from clinicians and the beauty industry alike: rapid, diffuse facial fat loss that leaves some patients looking gaunt or significantly older than before treatment. The informal term 'Ozempic face' describes this pattern of volume depletion around the cheeks, temples, and under-eye area. For Canadians currently on a GLP-1 receptor agonist, or considering one, the question is whether this is a cosmetic nuisance, a clinical concern, or something in between — and what, if anything, can be done about it.

Health Canada has approved both Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) and Wegovy (semaglutide 2.4 mg) for their respective indications. Ozempic is listed on several provincial formularies for type 2 diabetes, including Ontario's Ontario Drug Benefit (ODB) program and Quebec's RAMQ, though coverage criteria vary. Wegovy's provincial pharmacare coverage remains inconsistent: as of October 2026, most provinces do not list it as a standard benefit for obesity, meaning many patients pay out of pocket, often CAD $300 to $500 per month. The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a position statement specific to GLP-1 drugs and body composition changes. The Canadian Medical Association Journal (CMAJ) has published commentary on GLP-1 prescribing patterns but has not addressed facial changes specifically.

What changed

A October 21, 2026 Reuters report, picked up by CTV News, documented a coordinated push by major beauty and aesthetics companies to develop and market products aimed at GLP-1 users experiencing facial volume loss. The commercial logic is straightforward: global GLP-1 prescriptions have grown sharply since 2022, and the patient population losing significant weight is large enough to constitute a new consumer segment. Companies are positioning everything from collagen-stimulating skincare to injectable filler protocols as solutions to Ozempic face.

The underlying physiology is not disputed. GLP-1 receptor agonists work partly by suppressing appetite and slowing gastric emptying, producing caloric deficits that lead to weight loss. Fat is lost throughout the body, including the face, where subcutaneous fat provides structural support to overlying skin. When that fat diminishes faster than skin elasticity can adapt, the result can be sagging, hollowing, and a more aged appearance. This is not unique to semaglutide: any rapid, significant weight loss can produce similar changes. What is different now is the scale of the population experiencing it simultaneously, and the speed at which commercial interests have moved to address it.

Dermatologists and plastic surgeons in Canada have begun seeing patients asking about facial rejuvenation specifically in the context of GLP-1 use. Hyaluronic acid fillers, poly-L-lactic acid (Sculptra), and calcium hydroxylapatite (Radiesse) are the injectable options most commonly discussed in this context. These are regulated as medical devices by Health Canada, and their administration requires a licensed practitioner.

What this means in Canada

Health Canada has not issued any guidance specific to facial changes associated with GLP-1 drugs. The agency's approvals for Ozempic and Wegovy are based on glycemic control and weight reduction outcomes; cosmetic or dermatological sequelae are not part of the product monographs in any actionable way.

For Canadians on provincial pharmacare, the drug cost question is separate from the question of managing side effects. Injectable fillers and related aesthetic procedures are not covered by any provincial health plan in Canada, including OHIP in Ontario, RAMQ in Quebec, MSP in British Columbia, or AHCIP in Alberta. Patients who develop significant facial volume loss and want to address it will pay privately. A single syringe of hyaluronic acid filler in a Canadian clinic typically costs CAD $700 to $1,200, and multiple syringes are often needed.

Canadian telehealth platforms that prescribe GLP-1 medications, including Felix (a Canadian online pharmacy and prescribing platform) and Maple (a Canadian virtual care platform), do not currently provide integrated dermatology or aesthetics follow-up. Cleo, a Canadian women's health platform, and Science & Humans (scienceandhumans.com), a Canadian hormone and metabolic health clinic, similarly focus on the prescribing and monitoring side rather than cosmetic management. Patients seeking aesthetic intervention would need to consult a separate dermatologist or plastic surgeon.

The SOGC has not yet issued a position statement on GLP-1 use in the context of women's health more broadly, including perimenopausal or postmenopausal patients, who may already have reduced skin collagen and are potentially more susceptible to visible facial changes with rapid weight loss.

What Canadian patients should know

Facial fat loss during GLP-1 treatment is real and reported by a meaningful subset of patients, though no large Canadian cohort study has quantified its prevalence. The rate of weight loss appears to matter: faster loss is associated with more pronounced skin laxity. Some clinicians suggest that titrating the dose more slowly, or incorporating resistance training to preserve lean mass, may reduce the severity of body composition changes, though this has not been studied specifically for facial outcomes.

If you are on semaglutide or another GLP-1 drug and concerned about facial changes, the first step is a conversation with the prescribing physician or nurse practitioner. They can assess whether the rate of weight loss is appropriate for your health goals and whether any adjustment is warranted. A referral to a dermatologist is reasonable if skin changes are significant.

Be cautious about beauty products marketed specifically for 'Ozempic face.' Topical skincare, regardless of how it is positioned, cannot replace lost subcutaneous fat. Products claiming to 'restore volume' through a cream or serum are making claims that go beyond what the evidence supports. Health Canada regulates cosmetic claims, and products making therapeutic claims without approval would be in violation of the Food and Drugs Act.

For patients considering injectable fillers or other aesthetic procedures, choose a practitioner licensed in Canada, ideally a physician or nurse practitioner with specific training in facial anatomy and injectables. The Canadian Society of Plastic Surgeons and the Canadian Dermatology Association both maintain practitioner directories.

Provincial differences matter here too. In Quebec, certain aesthetic procedures can only be performed by physicians, while other provinces allow registered nurses with additional training to administer injectables. Confirm scope of practice in your province before booking.

Limitations and open questions

The term 'Ozempic face' is colloquial, not a clinical diagnosis. No peer-reviewed study has established its prevalence, severity distribution, or whether it differs between semaglutide and other GLP-1 drugs such as tirzepatide (sold in Canada as Mounjaro). The Canadian Institutes of Health Research (CIHR) has not funded a study on this specific outcome as of this writing.

It is also not clear whether facial volume loss is reversible if the drug is stopped and weight is regained, or whether the skin laxity persists. The beauty and aesthetics industry has a financial interest in framing this as a problem requiring their products. That framing may or may not align with what patients actually experience or need.

Health Canada has not issued guidance, the SOGC has not issued a position statement, and the CMAJ has not published clinical recommendations on managing GLP-1-associated body composition changes in the face. Until that evidence base exists, patients are navigating this largely on their own, with commercial interests filling the information gap.